Mechanism of Action
NPR-A Receptor Activation
Nesiritide binds NPR-A (guanylyl cyclase-A receptor) on vascular smooth muscle, renal tubular cells, and cardiac fibroblasts. NPR-A intrinsic guanylyl cyclase activity raises intracellular cGMP, activating protein kinase G (PKG). PKG phosphorylates myosin light chain phosphatase, causing smooth muscle relaxation and vasodilation, and activates renal epithelial targets to increase sodium excretion.
Hemodynamic Effects
Nesiritide produces balanced arterial and venous dilation, reducing pulmonary capillary wedge pressure (PCWP), right atrial pressure, and systemic vascular resistance. Cardiac output may increase modestly. These hemodynamic changes reduce myocardial oxygen demand and relieve the congestive symptoms of ADHF. Unlike nitroglycerin, nesiritide has sustained hemodynamic effects without rapid tolerance development.
Research Summary
ASCEND-HF Trial
FDA ApprovedASCEND-HF (n=7141): nesiritide significantly reduced dyspnea vs placebo (44.5% vs 42.1%) but did not improve 30-day mortality or hospitalization rates. No significant increase in mortality or renal dysfunction (earlier concerns with observational data). Modest symptom relief with good safety profile when used as adjunct to standard diuretic therapy.
Renal Function Concerns
ResolvedEarly meta-analyses (Sackner-Bernstein et al., 2005) suggested increased mortality and worsening renal function, leading to reduced clinical use. ASCEND-HF definitively showed no significant renal dysfunction or mortality increase, restoring confidence in appropriate use for symptom relief in ADHF.
Calculate your Nesiritide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| ADHF symptom relief | 2 mcg/kg IV bolus over 60 seconds, then 0.01 mcg/kg/min continuous infusion; may increase by 0.005 mcg/kg/min every 3 hours to max 0.03 mcg/kg/min | Continuous infusion | Intravenous |
Omit bolus if hypotension risk is high. Monitor BP every 30 minutes during initiation. Discontinue if systolic BP falls below 90 mmHg.
Interactions
Safety Profile
Most common adverse effect: hypotension (symptomatic in 4%, dose-dependent). Asymptomatic hypotension is more common and manageable by dose reduction. Headache and nausea occur. ASCEND-HF confirmed no significant worsening of renal function or increase in mortality vs placebo. Contraindicated in cardiogenic shock, systolic BP <90 mmHg, or significant valvular stenosis. Not appropriate for use without hemodynamic monitoring capability. Cost considerations have limited use relative to inexpensive loop diuretics.
References
- [1]O'Connor CM, et al. Effect of nesiritide in patients with acute decompensated heart failure (ASCEND-HF). N Engl J Med. 2011;365(1):32-43.
- [2]Publication Committee for the VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. JAMA. 2002;287(12):1531-1540.